TiGenix strengthens its product portfolio and biomaterials platform through the acquisition of Orthomimetics, a privately held medical technology company based in Cambridge, the United Kingdom. This acquisition fits with TiGenix’ growth strategy of becoming a leading player in the promising and fast-growing field of regenerative medicine. Orthomimetics’ flagship product, Chondromimetic™, is an off-the-shelf, resorbable implant for the minimally invasive repair of small osteochondral (cartilage and underlying bone) defects.

AlterG, Inc. has developed an anti-gravity treadmill using NASA technology that can provide users the feeling of moving about in less than 1 G. Anti-gravity treadmills. It is being sold under the name of Alter-G and is becoming common in hospitals, rehab centers, and sports facilities. Anti-G treadmills allow people to improve mobility and health, recover from injury and surgery more effectively, overcome medical challenges that limit movement, and enhance physical performance.

University of Pennsylvania researchers have found that the investigational biologic agent tocilizumab appeared to prevent joint erosion among rheumatoid arthritis patients better than treatment with methotrexate alone. Over a two-year period, 75% of the people taking tocilizumab 4 mg/kg showed no radiographic progression or joint damage compared with 66% of patients taking methotrexate alone (P=0.0239).

University of Pennsylvania School of Medicine researchers said that the investigational biologic agent tocilizumab appeared to prevent joint erosion among rheumatoid arthritis patients better than treatment with methotrexate alone. Over a two-year period, 75% of the people taking tocilizumab 4 mg/kg showed no radiographic progression or joint damage compared with 66% of patients taking methotrexate alone (P=0.0239).